OrthoDx
OrthoDx were proud to attend the Australian Orthopaedic Association (AOA) conference in November 2023, where we were able to showcase our first product, Synvichor, to the Australian market.
OrthoDx, in partnership with Revolution Surgical, held a dinner meeting where Dr Antony Rapisarda and A/Prof Kevin Tetsworth presented on the development and clinical applications of Synvichor.
Synvichor is a PCR based, genomic diagnostic assay that examines the gene expression of the patient’s own host response in the presence of the various causes of joint pain. Synvichor is then able to report this host response using proprietary algorithmic methods to inform the clinician of the presence or absence of infection.
The questions from the audience highlighted the potential of Synvichor to improve patient outcomes and provide significant financial savings for our healthcare system.
It was wonderful to speak with so many colleagues and customers during the AOA. Thank you to everyone who came along and made the event such a great success.
If you would like to know more about the world’s first genomic PCR test for rapid differentiation of joint pain, please get in touch with us today at info@orthodx.com.au
